摘要
目的探讨程序性死亡分子配体1(PD-L1)的表达与小细胞肺癌(SCLC)患者临床病理特征和预后的关系。方法回顾性分析郑州大学第一附属医院2013年1月至2016年12月收治的64例SCLC患者的临床病理资料,分析PD-L1表达与SCLC患者临床病理特征和预后的关系。结果免疫组化检测结果显示,PD-L1在SCLC患者中的阳性表达率为60.9%(39/64)。PD-L1在SCLC中的表达与分期有关(P<0.001)。单因素分析结果显示,PD-L1阴性表达组患者的中位总生存时间为16个月,明显长于PD-L1阳性表达组(14个月,P<0.001)。PD-L1阴性表达组患者的中位无进展生存时间为15个月,明显长于PD-L1阳性表达组(9个月,P<0.000 1)。多因素分析结果显示,PD-L1的阳性表达是影响SCLC患者无进展生存时间的独立危险因素(P=0.006)。结论 PD-L1在SCLC患者中高表达,PD-L1阳性表达是SCLC的独立不良预后因素。
Objective To explore the correlation between programmed death ligand 1 (PD-L1) expression and clinicopathological features and prognosis of small cell lung cancer (SCLC). Methods The clinicopathological data of 64 patients with small cell lung cancer from January 2013 to December 2016 in the First Affiliated Hospital of Zhengzhou University were retrospectively analyzed in this study. The correlation between PD-L1 expression and the clinicopathological features and prognosis of SCLC was analyzed. Results Immunohistochemical staining revealed that PD-L1 expression was observed in 60.9%(39/64) of patients with small cell lung cancer. PD-L1 expression was significantly related to stages (P<0.001). Univariate analysis showed that the median overall survival of PD-L1 negative group was longer than PD-L1 positive group (16 months vs 14 months, P<0.001). Median progression-free survival of PD-L1 negative group was longer than PD-L1 positive group(15 months vs 9 months, P<0.000 1). In multivariate analysis, PD-L1 positive was significantly correlated with inferior progression-free survival (P=0.006). Conclusions PD-L1 expression rate was high in small cell lung cancer. PD-L1 expression was an independent predictor for poor prognosis of patients with small cell lung cancer.
作者
邱亚娟
张明智
Qiu Yajuan;Zhang Mingzhi(Department of Respiratory,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2019年第3期214-217,共4页
Chinese Journal of Oncology
关键词
癌
小细胞肺
程序性死亡分子配体1
预后
Neoplasms, small cell lung
Programmed death ligand 1
Prognosis
